Formosa Pharmaceuticals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	9.5	143.36	31.17	1.32	28.53
Revenue Growth (YoY)	-93.38%	359.89%	2270.49%	-95.39%	-
Cost of Revenue	11.09	24.37	3.83	0.98	0.27
Gross Profit	-1.6	118.99	27.35	0.33	28.26
Selling, General & Admin	47.63	60.8	40.2	25.53	20.65
Research & Development	121.38	226	270.18	356.47	387.62
Operating Expenses	169.01	294.62	310.38	382	408.27
Operating Income	-170.61	-175.63	-283.04	-381.67	-380.01
Interest Expense	-0.49	-0.57	-4.31	-0.99	-2.21
Interest & Investment Income	25.29	21.18	12.42	0.47	0.06
Currency Exchange Gain (Loss)	-	-18.62	9.29	-25.15	20.97
Other Non Operating Income (Expenses)	61.8	1.03	0.09	0.75	0.01
EBT Excluding Unusual Items	-84	-172.61	-265.54	-406.59	-361.18
Gain (Loss) on Sale of Assets	-	-	-	-	-0.2
Other Unusual Items	-	-6.96	-34.53	-	-37.04
Pretax Income	-84	-179.57	-300.07	-406.59	-398.42
Income Tax Expense	-0.43	21.36	21.86	-0.42	2.4
Earnings From Continuing Operations	-83.57	-200.93	-321.93	-406.17	-400.82
Minority Interest in Earnings	0.01	-0.08	-0.03	-0.1	-0.06
Net Income	-83.57	-201.01	-321.96	-406.27	-400.88
Net Income to Common	-83.57	-201.01	-321.96	-406.27	-400.88
Shares Outstanding (Basic)	152	141	124	105	92
Shares Outstanding (Diluted)	152	141	124	105	92
Shares Change (YoY)	7.90%	13.48%	18.00%	13.70%	31.19%
EPS (Basic)	-0.55	-1.43	-2.59	-3.86	-4.33
EPS (Diluted)	-0.55	-1.43	-2.59	-3.86	-4.33
Free Cash Flow	-105.65	-135.95	-198.21	-346.15	-331.35
Free Cash Flow Per Share	-0.69	-0.96	-1.60	-3.29	-3.58
Gross Margin	-16.83%	83.00%	87.73%	25.32%	99.06%
Operating Margin	-1796.85%	-122.51%	-907.98%	-29024.26%	-1332.01%
Profit Margin	-880.10%	-140.22%	-1032.84%	-30895.21%	-1405.18%
Free Cash Flow Margin	-1112.70%	-94.83%	-635.85%	-26323.19%	-1161.46%
EBITDA	-121.05	-139.99	-247.53	-345.56	-345.41
EBITDA Margin	-	-97.65%	-	-	-
D&A For EBITDA	49.56	35.64	35.51	36.11	34.6
EBIT	-170.61	-175.63	-283.04	-381.67	-380.01
EBIT Margin	-	-122.51%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.